Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide.
D000230:Adenocarcinoma / Q000503:physiopathology*; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002460:Cell Line; D002472:Cell Transformation, Viral; D003110:Colonic Neoplasms / Q000503:physiopathology*; D003169:Complement Inactivator Proteins / Q000494:pharmacology; D003619:Dansyl Compounds; D006801:Humans; D008545:Melanoma / Q000503:physiopathology*; D051379:Mice; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000503:physiopathology; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D013539:Simian virus 40 / Q000235:genetics
D003169:Complement Inactivator Proteins; D003619:Dansyl Compounds; C019162:dansylarginine N-(3-ethyl-1,5-pentanediyl)amide; D001120:Arginine